U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within the pharmaceutical division called ...

In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, talks about the factors that are impacting the ...

Number 5: Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by strong denosumab biosimilars and expanding portfolios. Number 4: ...

President Donald J. Trump has signaled that lowering the costs of prescription drugs will be a priority for his second term.

Switching to Humira biosimilars saved Navitus clients more than $315 million in upfront costs in 2024 and resulted in a 60% ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...

As global markets navigate the complexities of trade policies and inflation trends, Asian economies are showing resilience amid these external pressures. In this environment, growth companies with ...

WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves ... This is not the complete list of all the ...

“As our data show, on average, patients paid more than 4 times as much out of pocket per month for Humira compared to Hadlima,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands ...